Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Arrowhead Pharma (NQ: ARWR )

23.27 -2.80 (-10.74%)
Streaming Delayed Price Updated: 2:16 PM EST, Dec 4, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Arrowhead Pharma

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Third Quarter Results
From Arrowhead Pharmaceuticals Inc.
Via Business Wire
Arrowhead Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Russell 2000 Traders Place Bearish Bets Via IWM ETF
The iShares Russell 2000 ETF (NYSE: IWM) has been trading sideways for the better part of the last six months between $211 and its all-time high of $234.53 from March 15. IWM... 
Via Benzinga
Arrowhead's Big Sell-Off Presents Buying Opportunity, According to HC Wainwright
The sell-off on shares of Arrowhead Pharmaceuticals Inc (NASDAQ: 
Via Benzinga
Arrowhead's ARO-HIF2 Shows Early Signs Of Efficacy In Type Of Kidney Cancer
Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) has announced interim results from the first two cohorts of Phase 1b study of ARO-HIF2 for clear cell renal cell... 
Via Benzinga
Arrowhead Announces Positive Interim Results from Phase 1b Study of ARO-HIF2 for Treatment of Clear Cell Renal Cell Carcinoma
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Mid-Afternoon Market Update: Silver Rises 2%; Alector Shares Spike Higher
Toward the end of trading Friday, the Dow traded up 0.46% to 34,792.90 while the NASDAQ rose 0.67% to 14,619.12. The S&P also rose, gaining 0.66% to 4,348.47. The U.S. has the... 
Via Benzinga
Topics Stocks
Exposures US Equities
S&P 500 Logs Another Record High as "Fear Gauge" Dips
Stocks are modestly in the black midday, thanks to upbeat monthly jobs data that showed 850,000 jobs were added in June. 
Via Talk Markets
Topics Stocks
Exposures US Equities
56 Biggest Movers From Friday
Gainers Sequential Brands Group, Inc. (NASDAQ: SQBG) jumped 89.2% to settle at $15.70. Eco Wave Power Global AB (NASDAQ: WAVE) shares surged 73.2% to close at $18.79. A 13G... 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers Alector (NASDAQ:ALEC) shares moved upwards by 52.47% to $34.17 during Friday's regular session. Alector's stock is trading at a volume of 26.9 million... 
Via Benzinga
Arrowhead Stock Plunges, Alector Stock Surges On Drug News
Arrowhead paused a drug study; Alector teamed up with GlaxoSmithKline to develop two drugs. Arrowhead stock sank, while Alector stock surged. 
Via Investor's Business Daily
Mid-Day Market Update: Dow Surges Over 100 Points; Arrowhead Pharmaceuticals Shares Plummet
Midway through trading Friday, the Dow traded up 0.33% to 34,747.45 while the NASDAQ rose 0.50% to 14,594.85. The S&P also rose, gaining 0.47% to 4,340.12. The U.S. has the... 
Via Benzinga
Topics Stocks
Exposures US Equities
Here's Why Arrowhead Pharmaceuticals Stock Is Getting Hammered Today
A paused clinical trial with an important asset wasn't what investors wanted to hear today. 
Via The Motley Fool
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers Alector (NASDAQ:ALEC) stock moved upwards by 39.93% to $31.36 during Friday's pre-market session. The market value of their outstanding shares is at $2.5... 
Via Benzinga
Arrowhead Stock Drops After RNAi Therapeutic Shows Lung Inflammation In Animal Models
Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) has voluntarily paused the AROENaC1001 Phase 1/2 study evaluating ARO-ENaC for cystic fibrosis. ARO-ENaC is the... 
Via Benzinga
Arrowhead Pauses ARO-ENaC Phase 1/2 Clinical Study
From Arrowhead Pharmaceuticals Inc.
Via Business Wire
Arrowhead Pharmaceuticals Initiates Phase 2b Study of Investigational ARO-ANG3 for Treatment of Mixed Dyslipidemia
From Arrowhead Pharmaceuticals Inc.
Via Business Wire
Arrowhead Presents Additional Clinical Data on Investigational ARO-AAT Treatment in Patients with Alpha-1 Liver Disease at EASL International Liver Congress
From Arrowhead Pharmaceuticals Inc.
Via Business Wire
Arrowhead Presents Preclinical Data on ARO-DUX4 at FSHD Society International Research Congress
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
The Daily Biotech Pulse: Lilly Spikes On Alzheimer's Drug Regulatory Filing Plan, Applied Genetics, Arcus Issue Data Readouts, Adcom Test Awaits Incyte, Monte Rosa Prices IPO
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 23) AngioDynamics, Inc. (NASDAQ... 
Via Benzinga
Arrowhead Presents Positive Interim Clinical Data on ARO-HSD Treatment in Patients with Suspected NASH at EASL International Liver Congress
From Arrowhead Pharmaceuticals Inc.
Via Business Wire
Horizon Acquires Rights to Arrowhead's RNAi-Based Gout Treatment Candidate
Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) and Horizon Therapeutics plc (NASDAQ: HZNP) have entered into a global collaboration and license agreement ... 
Via Benzinga
Arrowhead Pharmaceuticals and Horizon Therapeutics Announce Collaboration to Develop RNAi Therapeutic for Uncontrolled Gout
From Arrowhead Pharmaceuticals, Inc. and Horizon Therapeutics plc
Via Business Wire
The Week In Charts - Why You Can't Trade, Or Maybe You Can?
In this video, I look at the reasons for why you may or may not be able to trade. I also continue my discussion on finding 
Via Talk Markets
Biotech Movers During ASCO Week
The biotech sector performed well in a good ASCO week. And many biotech stocks were movers this week as a bullish sentiment took hold sparked by the Biogen Aduhelm approval. 
Via Talk Markets
Vertex Pharma Stumbles In Rare-Disease Effort, Buoying Rival Arrowhead Pharma
Vertex Pharmaceuticals scrapped development of a rare-disease treatment Thursday that appeared unlikely to benefit patients, and VRTX stock plunged. 
Via Investor's Business Daily
Arrowhead Pharmaceuticals Initiates Phase 2b Study of Investigational ARO-APOC3 for Treatment of Severe Hypertriglyceridemia
From Arrowhead Pharmaceuticals Inc.
Via Business Wire
Arrowhead Pharmaceuticals to Participate in Upcoming Conferences
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Arrowhead Receives $10M Option Exercise Fee From Janssen
Janssen Pharmaceuticals Inc, part of Johnson & Johnson (NYSE: JNJ), has delivered written notice of its intent to exercise its option right for ARO-JNJ1.... 
Via Benzinga
Arrowhead Earns $10 Million Option Exercise Fee
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.